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Abstract
The supporting role of urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor 1
(PAI-1) in migration and invasion is well known. In addition, both factors are key components in cancer cell–
related signaling. However, little information is available for uPA and PAI-1–associated signaling pathways in pri-
mary cancers and corresponding lymph node metastases. The aim of this study was to compare the expression
of uPA and PAI-1–associated signaling proteins in 52 primary breast cancers and corresponding metastases. Pro-
teins were extracted from formalin-fixed paraffin-embedded tissue samples of the primary tumors and metastases.
Protein lysates were subsequently analyzed by reverse phase protein array for the expression of members of the
PI3K/AKT (FAK, GSK3-β, ILK, pGSK3-β, PI3K, and ROCK) and the MAPK pathways (pp38, pSTAT3, and p38). A solid
correlation of uPA expression existed between primary tumors and metastases, whereas PAI-1 expression did not
significantly correlate between them. The correlations of uPA and PAI-1 with signaling pathways found in primary
tumors did not persist in metastases. Analysis of single molecules revealed that some correlated well between
tumors and metastases (FAK, pGSK3-β, ILK, Met, PI3K, ROCK, uPA, p38, and pp38), whereas others did not (PAI-1
and GSK3-β). Whether the expression of a protein correlated between tumor and metastasis or not was independent
of the pathway the protein is related to. These findings hint at a complete deregulation of uPA and PAI-1–related signal-
ing in metastases, which might be the reason why uPA and PAI-1 reached clinical relevance only for lymph node–
negative breast cancer tissues.
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Introduction
The supporting role of urokinase-type plasminogen activator (uPA), its
receptor uPAR, and the plasminogen activator inhibitor 1 (PAI-1) in
cell migration and invasion is well described in both physiologic
[1,2] and pathologic settings (for review, see McMahon and Kwaan
[3]). Since the late 1980s, uPA and PAI-1 have been considered as clin-
ically relevant predictive markers [4,5], and today, these findings are
well confirmed (for review, see Schmitt et al. [6]). The levels of uPA
and PAI-1 in the primary tumors of patients with node-negative breast
cancer are used clinically to decide which patients require chemo-
therapy and which do not [7].
The soluble protein uPA is known to inhibit apoptosis [8,9] and
actively induce proliferative signaling cascades, for example, the STAT3
pathway [10]. The main inhibitor of uPA, PAI-1, also has effects on
cell adhesion and modulates intracellular signaling, primarily through
up-regulation of apoptotic pathways [11,12]. The related signaling
cascades are not well known. In a model of vascular smooth muscle
cells, elevated levels of PAI-1 suppress apoptosis by directly interacting
with and inhibiting the dominant death caspase 3 [13]. In different
studies, PAI-1 was either upregulated or downregulated by the PI3K/
AKT signaling pathway [14,15].
These results demonstrate that the functions of uPA and PAI-1 sig-
naling are well described in cell culture systems. However, corre-
sponding data for primary breast cancer tissues are very limited. We
recently set up the assumption that PAI-1 might be associated mainly
with PI3K/AKT signaling, whereas uPA may correlate with activation
of ERK [16]. Herein, we used a reverse-phase protein array (RPPA)
approach to analyze the proposed interaction of uPA and PAI-1 with
ERK- and PI3K/AKT–related signaling cascades, respectively.
An additional matter discussed quite controversially in literature is
the expression and/or activation of different signaling proteins in pri-
mary tumors and lymph node metastases [17–20]. However, no
studies comparing uPA and PAI-1 expression and signaling in primary
tumors versus lymph node metastases have been completed so far. Be-
cause the uPA/PAI-1 system not only is involved in early metastatic
processes like cell detachment and migration but also plays important
roles in inhibition of apoptosis, proliferation, and vascularization, we
compared uPA- and PAI-1–associated signaling pathways in primary
tumors and lymph node metastases.
Materials and Methods
Antibodies
The following 14 proteins were analyzed in this study: PAI-1, uPA,
pER, focal adhesion kinase (FAK), glycogen synthase kinase 3-β
(GSK3-β), phosphorylated GSK3-β, HSP27, integrin linked kinase
(ILK), MET, phosphatidylinositol 3-kinase (PI3K), p38 MAP kinase
(p38), phosphorylated p38 (pp38), Rho-associated kinase (ROCK),
phosphorylated signal transducer and activator of transcription 3
(pSTAT3). Table W1 lists the antibodies against these proteins used
in RPPAs. All antibodies have been validated by Western blot analysis
using proteins extracted from formalin-fixed tissues or cells as described
before [16]. Specificity of the antibodies is shown in Figure W1.
Tissue Samples
Formalin-fixed paraffin-embedded primary breast cancer tissues
from 52 patients diagnosed between 2000 and 2008 were selected
from the archive at the Institute of Pathology, Technische Universität
München, Germany. In addition, the 52 corresponding lymph node
metastases were also used in the study. Patients’ characteristics are
summarized in Table W2. Figure W2 provides an overview of the
collectives and the workflow for their analysis.
The study was approved by the ethics committee of the Technische
Universität München, and all patients gave informed consent. Reference
hematoxylin/eosin–stained sections of the tissues were histologically
verified by an experienced pathologist (A.W.). Only tissue sections con-
taining more than 80% tumor cells were included in the study.
Protein Extraction
Protein extraction was performed as previously described [21],
using buffer EXB Plus (Qiagen, Hilden, Germany) [22]. Briefly,
tissue sections were deparaffinized, and proteins were extracted
using EXB Plus. Tissue areas of approximately 0.25 cm2 from three
10-μm-thick sections were processed in 100 μl of extraction buffer.
The Bradford protein assay (BioRad, Hercules, CA) was used ac-
cording to the manufacturer’s instructions to determine the protein
concentrations. A Western blot probing for β-actin was performed
from randomly selected lysates to demonstrate successful protein
extraction and suitability for RPPA analysis. All protein lysates tested
produced a clear β-actin band on the Western blot.
Reverse-Phase Protein Arrays
RPPAs were generated using the Aushon 2470 Arrayer (Aushon,
Billerica, MA) or BioOdyssee Calligrapher (Biorad, Hercules, CA)
as described before [23]. For every lysate and every dilution (un-
diluted, 1:2, 1:4, 1:8, 1:16, buffer), three replicates were applied onto
a nitrocellulose-coated glass slide (Grace Bio-Labs, Bend, OR), which
produced 18 data points per sample. Immunodetection was per-
formed like for a Western blot and as previously described [24]. For
the estimation of total protein amounts, parallel arrays were stained
with Sypro Ruby Protein Blot Stain (Molecular Probes, Eugene,
OR) according to the manufacturer’s instructions. For more detailed
information and method validation, see Wolff et al. [16].
Quantitative Protein Analysis
The scanned films (1200 dpi) of the antibody-detected slides were
saved as tiff images. These and the images of the Sypro Ruby–stained
slides were analyzed with MicroVigene 3.5.0.0 (VigeneTech, Carlisle,
MA) as described [25].
Statistical Analysis
The relationships between uPA or PAI-1 and the RPPA results, as
well as with continuous patient and tumor characteristics, were inves-
tigated using the Spearman rank correlation test. The associations of
uPA and PAI-1 levels with ordered clinical variables were tested using
the nonparametric Wilcoxon rank sum test or the Kruskal-Wallis
test. When appropriate, this was followed by a nonparametric test
for trend. All tests were performed using PASW Statistics software
version 18.0 (SPSS, Inc, Chicago, IL). To fit different linear regres-
sion lines to spread bivariate data, a mixture model was used [26,27].
Ninety-five percent of the confidence bands were provided for regres-
sion fit lines.
Holm-Bonferroni adjustment of P values was performed to correct
for multiple testing. Adjusted two-sided P values ≤ .05 were consid-
ered to indicate statistical significance.
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Results
Correlation of uPA and PAI-1 Expression with
PI3K/AKT- and MAPK Signaling in Primary Breast Cancers
As we recently revealed first hints to possible interactions of PAI-1
and uPA with AKT and MAP kinase signaling, respectively, in vivo
[16], we now examined the expression of uPA, PAI-1, and 12 further
signaling molecules composed of members of the PI3K/AKT (FAK,
GSK3-β, ILK, pGSK3-β, PI3K, and ROCK) and the MAPK pathways
(pp38, pSTAT3, and p38). Furthermore, we included HSP27, MET,
and pER to examine the relation of these tumor progression modulators
with uPA and PAI-1. HSP27 was described to interact with AKT be-
fore [28]. Protein levels of PAI-1 and uPA were correlated with the
expression levels of these key signaling proteins determined by RPPA.
The Spearman correlation coefficient rs and P values are listed in
Tables 1 and 2. All P values are adjusted for multiple testing as de-
scribed in the Materials andMethods section. Positive correlations were
found for PAI-1 with FAK, ILK, ROCK, and PI3K (Table 1). In ad-
dition, PAI-1 expression correlated positively with the levels of HSP27
and pp38. GSK3-β, ILK, MET, pGSK3-β, pHSP27, and pSTAT3 did
not correlate with PAI-1 levels. These results are in line with our sugges-
tion that PAI-1 is correlated with the PI3K/AKT pathway.
For uPA, we found positive correlations with FAK, HSP27, ILK,
pp38, and ROCK (Table 2). This fits with our expectation that uPA
might interact with the MAP kinase pathway but also hints at some
connectionwith cytoskeleton regulation through ILK, FAK, andROCK.
Also, uPA and PAI-1 correlated with each other in this study set.
Analysis of Pathway Activation in Single Tumors
Because we found FAK, ILK, PI3K, and ROCK to be correlated with
PAI-1, we wanted to know next if this connection of PI3K/AKT signal-
ing and PAI-1 can also be seen on a single-patient level. Expression levels
of PAI-1, FAK, ILK, PI3K, and ROCK detected in seven patients are
shown in Figure 1. The examples are representative and show coexpres-
sion of the molecules at the patient level. From the 52 cases analyzed,
only 4 showed a differential expression of a single molecule.
Correlation of Protein Expression in Primary Breast Cancers
versus Their Corresponding Lymph Node Metastases
As it is known that both uPA and PAI-1 play a role in the metastatic
cascade and are potentially involved in metastasis establishment by regu-
lation of vascularization, we analyzed uPA and PAI-1 expression in the
corresponding 52 lymph node metastases. The analysis revealed that
PAI-1 did not correlate between primary tumors and lymph node
metastases (rs = +0.137, P = .336). However, we found that two dis-
tinguishable groups exist within the patients regarding their PAI-1 ex-
pression profiles. These groups can be functionally described by linear
regression equations. For one group (A), the expression of PAI-1 in the
lymph node is always low and almost independent of PAI-1 expression
of the primary tumor. For the other patient group (B), the expression of
PAI-1 in primary tumors and lymph node metastases correlated with a
correlation coefficient of rs = +0.799 and P < .001 (Figure 2A). This
raised the question whether these two groups could be distinguished in
respect of the clinical classification of the patients. However, we could
not find any difference between the groups regarding their correlation
with nodal status, tumor size, grading, steroid hormone receptor status,
and occurrence of distant metastasis (data not shown).
In contrast, the expression of uPA correlated significantly between
primary tumors and corresponding lymph node metastases with a cor-
relation coefficient of rs = +0.566 and P < .001 (Figure 2B).
Because we found differential expression of uPA and PAI-1 in pri-
mary tumors and lymph node metastases, we also analyzed uPA- and
PAI-1–associated pathways in lymph node metastases. As expected, the
correlations found in primary tumors were not seen in lymph node
metastasis. Whereas we could not find any correlation between PAI-1
and the signaling molecules analyzed herein (Table 3), uPA expression
correlated with the expression of pp38 and pGSK3-β in lymph node
metastases (Table 4). Tables 3 and 4 list the Spearman correlation co-
efficients rs and P values. All P values are adjusted for multiple testing as
described in the Materials and Methods section. Because we could not
find the correlations for uPA and PAI-1 found in primary tumors to
persist in lymph node metastases, we next analyzed the correlation of
the expression levels of single molecules between primary tumors and
lymph node metastases. Whereas the expression of several molecules
(FAK, ILK, MET, pGSK3-β, PI3K, pp38, p38, ROCK, and uPA) cor-
related significantly between primary tumors and lymph node metas-
tases, the expression of GSK3-β and PAI-1 did not (Table W3).
Discussion
Signaling Pathways in Primary Breast Cancers
During the last few years, cell-based models have provided insight
into the binding and signaling of the members of the plasminogen
Table 1. Correlation of PAI-1 with Key Signaling Proteins Determined by RPPA.
PAI-1 vs rs P
FAK 0.495 .029
GSK3-β 0.103 >.999
pGSK3-β 0.297 >.999
HSP27 0.464 .047
ILK 0.451 .047
MET 0.286 >.999
p38 0.312 .676
pp38 0.482 .029
pER 0.212 >.999
PI3K 0.547 .010
pSTAT3 0.170 >.999
ROCK 0.491 .025
uPA 0.663 .000
The Spearman correlation coefficient rs and P values are shown. All P values are adjusted for mul-
tiple testing as described in the Materials and Methods section. Statistically significant correlations
are in bold face emphases.
Table 2. Correlation of uPA with Key Signaling Proteins Determined by RPPA.
uPA vs rs P
FAK 0.598 .002
GSK3-β 0.336 .543
pGSK3-β 0.468 .055
HSP27 0.579 .002
ILK 0.514 .012
MET 0.410 .151
p38 0.420 .102
pp38 0.584 .002
PAI-1 0.663 .000
pER 0.329 .610
PI3K 0.471 .072
pSTAT3 −0.013 .932
ROCK 0.574 .002
The Spearman correlation coefficient rs and P values are shown. All P values are adjusted for mul-
tiple testing as described in the Materials and Methods section. Statistically significant correlations
are in bold face emphases.
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activator system. Lately, we were able to confirm some of the cell
culture studies in mammary carcinoma, and we could integrate them
into a broader in vivo picture [16]. In the current study, we analyzed
uPA, PAI-1, and 12 proteins potentially involved in uPA and PAI-1
signaling. Related to the AKT pathway, we found PAI-1 to be pos-
itively correlated with FAK, PI3K, ROCK, and ILK (Figure W3). In
an earlier study of our institute, we could demonstrate PAI-1 correla-
tion with the integrin subunit αV and pAKT. Together, these find-
ings substantiate a positive correlation of PAI-1 with various members
of the PI3K/AKT pathway in breast cancer. These correlation results
were strengthened by the finding that there is clear coexpression of the
proteins of the PI3K/AKT pathway (FAK, PI3K, ROCK, and ILK)
with PAI-1 expression in individual patients. We found one of the five
proteins differentially expressed compared to the others in only 4 of
52 patients analyzed here. In the literature, it is controversially discussed
whether PAI-1 has an inhibiting or activating effect on the PI3K/AKT
pathway and thus on cell proliferation and survival [13–15]. However,
these studies were all realized in different cell culture models. Because of
our findings, we can now state that, in breast cancer tissue, in which
PAI-1 plays an important role in diagnosis, there is an activating con-
nection between the protein and the mentioned pathway. Furthermore,
the results strengthen the assumption that the PI3K/AKT pathway is a
major mediator on PAI-1–induced antiapoptotic activity. Because there
are PI3K inhibitors already tested in clinical trials, our findings may
be of clinical relevance. However, with our data, it is not possible to
predicate who is influencing who, especially because there is also evi-
dence that FAK, PI3K, ROCK, and ILK play a crucial role in the
induction of PAI-1 expression [11,12]. Because GSK3-β seems not
to be the preferential target of the PAI-1–induced signaling, additional
studies will be needed to further characterize the outcome of this
PI3K/AKT activation.
In addition to these core proteins of the AKT pathway, we also
found PAI-1 to correlate with pp38 and HSP27. Functional studies
demonstrated that an activation of p38 induces up-regulation of
PAI-1 expression [29]. Accordingly, an inhibition of p38 phosphor-
ylation leads to a decrease of PAI-1 levels [30,31]. Furthermore, it is
a known fact that, through MAPKAPK activation, pp38 leads to an
activation of HSP27 [32,33], which, in turn, stimulates activation
of ROCK [33]. Unfortunately, we did not analyze the activated
forms of HSP27 and ROCK, so that these findings could not be
verified for breast cancer tissue samples. Nevertheless, there is evi-
dence that, beside activation, p38 also increases the expression of
HSP27 [34]. Such an overexpression of HSP27 then in turn leads
to an up-regulation of PAI-1 [35]. Combined with the known facts
in the literature, the found correlations support the interactions of
PAI-1, p38, and HSP27.
For the correlation of uPA with cell signaling pathways, the results
we obtained are less clear than for PAI-1. We found uPA to correlate
with pERK but not pAKT in our previous study [16]. Here, we found
interactions of uPA with pp38 but also with ILK, FAK, ROCK, and
HSP27. Thus, we could not identify a single pathway that seems to be
preferentially involved in uPA-mediated signaling so far.
Expression Studies in Primary Tumors versus Lymph
Node Metastases
Analysis of the expression of uPA and PAI-1 in primary tumors
versus lymph node metastases revealed that, whereas uPA expression
correlated well between primary tumors and lymph nodes, PAI-1
seems to be differentially expressed in these entities. This finding
might explain why the prognostic value of uPA and PAI-1 expression
found in node-negative patients is lost in breast cancer patients bear-
ing lymph node metastases. While the primary tumor might still
Figure 1. Parallel analysis of FAK, ILK, PI3K, and ROCK expression in correlation to PAI-1 expression. A selection of seven representative
tumors is shown in the figure. Normalized signal intensity of the different proteins obtained by RPPA analysis is depicted. All four
proteins of the PI3K/AKT signaling pathway are expressed at similar levels compared with PAI-1 expression in six of seven patients.
For one patient (no. 186), a single protein (PI3K) is expressed in a different manner than the rest of the pathway. In only 4 of the analyzed
52 patients, a single protein was regulated in a different manner than the rest of the pathway.
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react to chemotherapy as predicted by the uPA/PAI-1 status, the cor-
relating lymph node metastases might be differentially regulated by
a different expression of PAI-1, thus changing the outcome for the
patient. The separation of the patients into two groups (compare
Figure 2A) is of special interest in this regard. Although we could
not correlate the two groups with any known clinical parameters
(grading, staging, tumor size, hormone receptor status, and occur-
rence of distant metastases), it is plausible to argue that the finding
might give a hint why analysis of uPA and PAI-1 in primary tumors
does not predict therapy outcome in patients with node-positive
breast cancer. The differences of PAI-1 expression in lymph node
metastases may at least in part account for the loss of predictive
value of uPA and PAI-1 seen in patients with node-positive cancers
so far. Thus, our data show that a reevaluation of the predictive
value of uPA and PAI-1 in node-positive patients taking the uPA
and PAI-1 status of lymph node metastases into account might be
auxiliary to further optimize patient stratification for chemotherapy
beyond the node-negative status.
In addition to the deregulation of PAI-1 in lymph node metastases,
we also found that uPA and PAI-1 correlated signaling was changed in
metastases compared with primary tumors. None of the correlations
found for PAI-1 in primary tumors is still present in metastases, hint-
ing at differential signaling regulation between primary tumor and
metastasis. On the basis of this assumption, we looked at the corre-
lation the proteins analyzed in this study (n = 14) between primary
tumor and metastasis individually. Here we found that, while most of
the proteins analyzed in this study (uPA, FAK, HSP27, ILK, MET,
p38, pER, pGSK3-β, PI3K, pp38, and pSTAT3) correlate between
primary tumors and lymph node metastases, PAI-1 and GSK3-β
did not (Table W3). This fits quite well with literature where differ-
ences of expression between primary tumors and their corresponding
lymph node metastases are discussed quite controversially. There are
studies demonstrating similar expressions of defined protein patterns
in primary tumors and the correlating lymph node metastases [18,20]
as well as such describing proteins to be differentially expressed in pri-
mary tumors and lymph node metastases [17,19]. Interestingly, a
study by Hao et al. [36] concluded that both findings may be true
depending on the individual protein analyzed. In our study, the
similar versus differential expression of single proteins cannot be asso-
ciated to distinct pathways, which indicates that the overall regulation
Figure 2. Correlations of uPA and PAI-1 expression in primary
tumors versus lymph node metastases. (A) PAI-1 expression did
not correlate in the two entities, rs = 0.094, P = .516, when ana-
lyzing all patients. Two groups (groups A and B) of PAI-1 expres-
sion could be discriminated by a statistical mixture model and
95% confidence intervals. In group A, PAI-1 expression can be
described by the quotation: PAI-1 expression in lymph node
metastases = 622.6 (relative expression units) + 0.02 × PAI-1
expression in primary tumors. In group B, PAI-1 expression can
be described by the quotation PAI-1 expression in lymph node
metastases = 587.7 (relative expression units) + 1.79 × PAI-1
expression in primary tumors. (B) A significant correlation of uPA
expression in primary tumors versus lymph node metastases, rs =
0.566, P ≤ .001, was found.
Table 3. Correlation of PAI-1 with Key Signaling Proteins Determined by RPPA in Lymph
Node Metastases.
PAI-1 vs rs P (two-sided)
FAK −0.041 >.999
GSK3-β −0.035 >.999
pGSK3-β 0.136 >.999
HSP27 −0.046 >.999
ILK 0.035 >.999
MET −0.035 >.999
p38 0.104 >.999
pp38 −0.023 >.999
pER 0.105 >.999
PI3K −0.019 >.999
pSTAT3 0.215 >.999
ROCK −0.029 >.999
uPA 0.264 >.999
The Spearman correlation coefficient rs and P values are shown. All P values are adjusted for mul-
tiple testing as described in the Materials and Methods section. Statistically significant correlations
are in bold face emphases.
Table 4. Correlation of uPA with Key Signaling Proteins Determined by RPPA in Lymph
Node Metastases.
uPA vs rs P (two-sided)
FAK 0.418 .073
GSK3-β 0.243 >.999
pGSK3-β 0.461 .030
HSP27 0.274 .106
ILK 0.217 >.999
MET 0.389 .144
p38 0.343 .374
pp38 0.456 .032
PAI 0.264 >.999
pER 0.367 .248
PI3K 0.199 >.999
pSTAT3 0.419 .074
ROCK 0.359 .293
The Spearman correlation coefficient rs and P values are shown. All P values are adjusted for mul-
tiple testing as described in the Materials and Methods section. Statistically significant correlations
are in bold face emphases.
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of protein expression may well differ between primary tumors and the
correlating lymph node metastases, thus leading to alternate signaling
activity and thereby influencing further metastatic potential as well
as therapy response.
In summary, we could pin down the correlation of PAI-1 expres-
sion with the PI3K/AKT pathway, whereas the results for uPA were
not as clear. We found uPA to correlate with proteins of the MAPK
pathway as well as with the PI3K/AKT pathway. The association
with the MAPK pathway is supported by our previous study [16].
To get insight into the correlation of uPA with the PI3K/AKT path-
way, further studies are planned. Furthermore, with this study, we
provided insight into the differential expression of proteins and path-
ways between primary tumors and metastases demonstrating that
there is no uniform change of expression between these entities. Re-
garding the potential of uPA and PAI-1 as predictive markers to strat-
ify patients for chemotherapy, our results provide an interesting
starting point to reevaluate the value of the factors in node-positive
patients with consideration of the uPA and PAI-1 expression in lymph
node metastasis.
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Figure W1. Validation of antibody specificity by Western blot analysis. All antibodies were validated using breast cancer FFPE tissue
samples unless stated otherwise.
Table W2. Patient and Disease Characteristics Related to the Collective of 52 Node-Positive
Patients Analyzed to Study Protein Expression Correlations between Primary Tumor and Lymph
Node Metastases.
Factor Patient Collective (n = 52)
No. Patients %
Age
<50 6 11.5
≥50 46 88.5
Tumor state
T1 11 21.2
T2 31 59.6
T3 7 13.5
T4 3 5.8
Nodal status
N1 22 42.3
N2 16 30.8
N3 14 26.9
Subtype
Ductal 38 73.1
Lobular 10 19.2
Ductal-lobular 2 3.8
Other 2 3.8
Distant metastasis
Positive 0 0.0
Negative 50 96.2
Unknown 2 3.8
Grading
1 1 1.9
2 24 46.1
3 27 51.9
Hormone receptor status
Positive 41 78.9
Negative 10 19.2
Unknown 1 1.9
Table W1. Proteins Analyzed and Antibodies Used in This Study.
Antibody Distributor Dilution
pS118ERα No. 2511 Cell Signaling, Danvers, MA 1:2000
FAK No. 3285 Cell Signaling, Danvers, MA 1:2000
GSK3-β No. 9315 Cell Signaling, Danvers, MA 1:1000
pS9GSK3-β No. 9336 Cell Signaling, Danvers, MA 1:1000
HSP27 No. 2402 Cell Signaling, Danvers, MA 1:1000
ILK No. 3856 Cell Signaling, Danvers, MA 1:2000
MET No. 3127 Cell Signaling, Danvers, MA 1:1000
PAI-1 AHP1100 Serotec, Oxford, United Kingdom 1:5000
PI3K No. 4292 Cell Signaling, Danvers, MA 1:1000
p38 No. 9212 Cell Signaling, Danvers, MA 1:1000
pT180/Y182p38 No. 4631 Cell Signaling, Danvers, MA 1:1000
ROCK No. 4035 Cell Signaling, Danvers, MA 1:1000
pS727STAT3 No. 9136 Cell Signaling, Danvers, MA 1:1000
uPA Ab19893 Abcam, Cambridge, United Kingdom 1:500
Figure W2. Strategy for the analysis of the collective used in this study.
Table W3. Correlation of the Expression of the 14 Analyzed Signaling Molecules between Primary
Tumors and Lymph Node Metastases.
rs P (two-sided)
FAK 0.597 .000
GSK3-β 0.270 >.999
pGSK3-β 0.646 .000
ILK 0.697 .000
MET 0.603 .001
PI3K 0.655 .000
ROCK 0.571 .000
pp38 0.576 .000
p38 0.651 .000
PAI-1 0.173 >.999
uPA 0.566 .008
pSTAT3 0.453 .000
pER 0.446 .000
The Spearman correlation coefficient rs and P values are shown. All P values are adjusted for mul-
tiple testing as described in the Materials and Methods section. Statistically significant correlations
are in bold face emphases.
Figure W3. Overview of pathways correlating with high PAI-1 expression (gray). PAI-1 expression was found to be correlated with sev-
eral proteins involved in AKT signaling (FAK, ILK, ROCK, and PI3K), supporting the assumption that PAI-1 is involved in the activation of
AKT through integrin αVβ3-induced PI3K activation. Furthermore, PAI-1 correlates with HSP27 and pp38, which are known to increase
PAI-1 expression through transcription factor activation.
